

### Challenge

A clinical-stage drug development company launched a Phase 2 trial for Cholestatic Pruritus, a rare and debilitating condition. The traditional site-based approach struggled to enroll patients, averaging just 0.1 per site per month—a common challenge in rare disease research due to geographic dispersion and strict eligibility criteria. Complex protocol requirements, including frequent visits, extensive record retrieval, and confirmed diagnosis, created a high burden for patients and sites, further slowing recruitment.

### Solution

By bringing the trial into patients' homes, Science 37 reduced burden and enabled participation despite demanding protocol requirements. Science 37's mobile research-grade nurses conducted in-home visits, managed complex data collection, and supported rapid remote screening. This approach accelerated enrollment, exceeded recruitment timeline expectations, and led the sponsor to expand Science 37's contracted capacity due to strong performance.

### Science 37 Results

Enrolled

**21%**

of Total Participants

Science 37 total pts – 13  
51 brick & mortar total pts – 43

**11x**

Faster Enrollment Compared  
to Traditional Sites

Science 37 avg. pts/month – 1

Single brick & mortar  
site avg. pts/month – 0.1

**Top  
Enrolling  
Site**

Among 52 Sites

**Exceeded  
Contracted  
Enrollment  
Goal**

enrollment exceeded original projections—  
contract was amended to allow for more  
participants due to strong performance

**“Science 37 was a pivotal part  
in reaching our goals for the trial.”**

Trial Sponsor



**Scan to Learn More about Our Direct-to-Patient Site.**

© 2025 Science 37. All rights reserved. This material is confidential and proprietary to Science 37 and shall not be distributed, edited or modified in any way without Science 37's advance written consent.

[www.science37.com](http://www.science37.com)




**The First & Only FDA-Inspected  
Direct-to-Patient Site**

Case Study: Cholestatic Pruritus

Phase 2 | Rare Disease, Dermatology

Enrollment Curve



Scan to Learn More about Our Direct-to-Patient Site.

© 2025 Science 37. All rights reserved. This material is confidential and proprietary to Science 37 and shall not be distributed, edited or modified in any way without Science 37's advance written consent.

[www.science37.com](http://www.science37.com)



The First & Only FDA-Inspected  
Direct-to-Patient Site